Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers ...

Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced ...

Of those 49 drugs, 39 were classified as having high added therapeutic benefit, and accounted for estimated post-rebate Medicare spending totaling $26 billion. But "cancer drugs o ...

and cemiplimab (Libtayo), an anti–PD-1 agent, in patients with advanced melanoma. 1 The first-in-human, phase 1, open-label, dose-escalation and cohort expansion trial sought to evaluate the safety ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...